文献速递白血病造血干细胞移植与细胞治疗

奥加伊妥珠单抗联合博舒替尼治疗复发/难治性费城染色体阳性急性淋巴细胞白血病或慢性髓系白血病淋巴样急变期

Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia.
PubMed 文献 · Am J Hematol · 2021-05-28

这项1/2期研究评估奥加伊妥珠单抗联合博舒替尼治疗复发/难治性费城染色体阳性急性淋巴细胞白血病(Ph+ ALL)或慢性髓系白血病淋巴样急变期(LBP-CML)的安全性和疗效。18例患者入组,博舒替尼最大耐受剂量为400 mg/d,83%患者达完全缓解(CR)/血小板未完全恢复的完全缓解(CRi),中位总生存13.5个月。

要点

  • 博舒替尼联合奥加伊妥珠单抗的最大耐受剂量为400 mg/d。
  • CR/CRi率达83%,61%患者流式检测微小残留病(MRD)阴性。
  • 中位随访44个月,中位缓解持续时间7.7个月,中位总生存13.5个月。

核心结论

  • 奥加伊妥珠单抗联合博舒替尼在复发/难治性Ph+ ALL和LBP-CML中耐受良好,并显示出疗效。

研究设计与样本

  • 1/2期研究,采用3+3设计,博舒替尼每日三个剂量水平(300 mg/d、400 mg/d、500 mg/d)。
  • 奥加伊妥珠单抗第一周期每周给药,后续每4周一次,共6个周期。
  • 入组18例患者(Ph+ ALL 16例,LBP-CML 2例),中位年龄62岁(范围19-74),中位既往治疗线数1(范围1-5)。
  • 排除T315I突变患者。

主要发现

  • 剂量限制性毒性包括3级皮疹,博舒替尼400 mg/d确定为最大耐受剂量。
  • 最常见的3/4级治疗中出现的不良事件为血小板减少(60%)和中性粒细胞减少(38%)。
  • 15/18(83%)患者达到CR/CRi,11/18(61%)患者流式细胞术检测MRD阴性,10/18(56%)患者达到完全分子学缓解。
  • 30天死亡率为0%,中位随访44个月,中位缓解持续时间和总生存分别为7.7个月和13.5个月。
  • 6例患者后续接受异基因造血干细胞移植,无患者发生肝窦阻塞综合征。

临床怎么用

  • 对于复发/难治性Ph+ ALL或LBP-CML患者,可考虑奥加伊妥珠单抗联合博舒替尼(400 mg/d)方案。
  • 治疗过程中需监测血小板减少和中性粒细胞减少等不良事件。

局限性

  • 样本量小(18例),为1/2期研究。
  • 排除T315I突变患者。
  • 随访时间有限,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapsed/refractory (R/R) Philadelphia chromosome positive acute lymphoblastic leukemia (Ph + ALL) and lymphoid blast phase of chronic myeloid leukemia (LBP-CML) have poor outcomes. We designed a phase 1/2 study combining inotuzumab ozogamicin with bosutinib for this patient population. Patients with T315I mutation were excluded. Bosutinib was administered daily at three dose levels (300 mg/d, 400 mg/d, 500 mg/d) in a 3 + 3 design. Inotuzumab ozogamicin was dosed weekly during cycle one, and once every 4 weeks subsequently for a total of six cycles. The primary objective was to determine the safety and the maximum tolerated dose (MTD) of bosutinib in combination with inotuzumab ozogamicin. Eighteen patients were enrolled (Ph-positive ALL, n = 16; LBP-CML, n = 2). The median age was 62 years (range, 19-74) and the median number of prior therapies was one (range, 1-5). Dose limiting toxicities included grade 3 skin rash and bosutinib 400 mg daily was determined as the MTD. The most frequent grade 3/4 treatment-emergent adverse events were thrombocytopenia (60%) and neutropenia (38%). A complete response (CR) / CR with incomplete count recovery (CRi) was achieved in 15/18 (83%) patients; 11/18 (61%) patients achieved negative measurable residual disease by flow cytometry. Complete molecular response was noted in 10/18 (56%) patients. The 30-day mortality was 0%. After a median follow-up of 44 months, the median duration of response and overall survival were 7.7 months and 13.5 months, respectively. Six patients had a subsequent allogeneic stem cell transplant. No patient developed veno-occlusive disease. Inotuzumab ozogamicin with bosutinib was well tolerated in R/R Ph-positive ALL and LBP-CML.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Jain N, Maiti A, Ravandi F, et al. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol. 2021. PMID: 33991360. doi:10.1002/ajh.26238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。